---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-108624"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2024-09-23T23:59:59+00:00"
generated_at: "2026-05-31T02:29:53.510900+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Invivyd provides virology data showing PEMGARDA neutralization potency stable against current SARS-CoV-2 variants

## Summary
- In vitro neutralization potency of PEMGARDA against KP.3.1.1 and LB.1 variants remains in-line with prior predominant variants dating to 2022.
- Structural analysis shows 19-key-amino-acid pemivibart binding site has de minimis mutational change and 99%+ stability since Omicron BA.1.
- Emerging variants XEC and LP.1 have mutations distal to binding site, not expected to meaningfully alter pemivibart activity; routine testing follows.
- Data from independent LabCorp Monogram Biosciences lab; company expects sustained neutralization based on structural biology.

## SEC filing metadata
- accession: 0000950170-24-108624
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2024-09-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000095017024108624/0000950170-24-108624-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000095017024108624/ivvd-20240923.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-108624
- JSON: https://secwatch.observer/filing/0000950170-24-108624.json
- Plain text: https://secwatch.observer/filing/0000950170-24-108624.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.